✦ LIBER ✦

Spironolactone in congestive heart failure

✍ Scribed by Judith E. Soberman; Karl T. Weber

Book ID: 107540863
Publisher: Springer
Year: 2000
Tongue: English
Weight: 260 KB
Volume: 2
Category: Article
ISSN: 1522-6417
DOI: 10.1007/s11906-000-0027-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Worsening of motor symptoms and gynecoma

Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure

✍ Hélio A.G. Teive; Renato P. Munhoz; Lineu C. Werneck 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 1 views

roradiological features beyond the typical cerebellar peduncle hyperintensities that were found minimal in this instance. FXTAS is expected to be less severe in females because of the presence of two X chromosomes, subject to random inactivation. It has been suggested that expression of the disease

Effects of spironolactone on serum and m

Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension

✍ T. Dyckner; P.-O. Wester; L. Widman 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 586 KB

Endothelin in congestive heart failure

✍ M. P. Love; J. J. V. McMurray 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 1011 KB

Nitrates in congestive heart failure

✍ Jocelyn Dupuis 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 699 KB

Congestive heart failure syndrome

📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB

Congestive heart failure I

📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 364 KB

Digoxin (D) can differently affect heart rhythm. 46 patients (pts) with CHF II-III NYHAFC (DCMP-26, RVD-14, and IHD-6) taking D therapy were studied. Pts took D during 6-12 months, then drug was discontinued, and in 5 days after this it was intravenously injected during 7-10 days in dose 0,75 rag da